Answers are grounded in this paper and cite their sources.
Clinicopathologic characterization reveals CDX2 expression and TP53 variants in endometrial carcinomas, indicating distinct features of EMCG.
Endometrial carcinoma of gastrointestinal-type (EMCG) is an aggressive endometrial cancer characterized by gastric and/or intestinal-type mucinous morphology, absent/minimal estrogen receptor expression, and at least focal gastrointestinal marker immunoexpression. We herein present a clinicopathologic characterization of 4 EMCG: 2 were prospectively diagnosed, and 2 found on retrospective screening of 274 endometrial carcinomas performed to identify undetected EMCG and characterize gastrointestinal marker expression within our endometrial carcinoma population. All 4 EMCG expressed CDX2 and were negative for SATB2; CK20 was diffuse in one, focal in another, and absent in 2. None showed strong membranous Claudin-18. One was MMR-deficient; 2 had PTEN loss. Sequencing revealed a variety of molecular events, including pathogenic/likely pathogenic variants KRAS, PIK3CA, POLE, PTEN, SMARCA4 , and TP53 . Thirty-six percent of retrospectively screened endometrial carcinomas expressed at least one gastrointestinal marker; however, the majority had strong ER co-expression, precluding EMCG classification. Other than the 2 cases of true EMCG identified on screening, only one screen-positive tumor had convincing gastrointestinal-type morphology in concert with ER negativity; this case showed SALL4 and AFP expression consistent with a somatically derived yolk sac tumor. These data provide an expanded understanding of the molecular underpinnings of EMCG—including the first description of a SMARCA4 frameshift variant in this entity—and demonstrate that while gastrointestinal marker immunoexpression is relatively common among endometrial carcinomas, strictly defined EMCG remains rare (<1%). As awareness of this entity grows, pathologists should take care not to over-interpret gastrointestinal marker expression as stand-alone evidence of an EMCG diagnosis.
No takes yet. Share an insight, caveat, or question.
Alzayadneh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: